Vitrolife Valuation
Is VITR undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of VITR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: VITR (SEK167.1) is trading below our estimate of fair value (SEK208.3)
Significantly Below Fair Value: VITR is trading below fair value, but not by a significant amount.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for VITR?
Other financial metrics that can be useful for relative valuation.
| What is VITR's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | SEK 22.62b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 6.8x |
| Enterprise Value/EBITDA | 21.3x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does VITR's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 14.7x | ||
BONEX Bonesupport Holding | 26x | 27.1% | SEK 17.8b |
BIOG B BioGaia | 9.6x | 11.8% | SEK 12.6b |
SOBI Swedish Orphan Biovitrum | 4.1x | 9.2% | SEK 97.1b |
HNSA Hansa Biopharma | 19.1x | 41.3% | SEK 3.1b |
VITR Vitrolife | 6.5x | 7.1% | SEK 23.4b |
Price-To-Sales vs Peers: VITR is good value based on its Price-To-Sales Ratio (6.5x) compared to the peer average (14.7x).
Price to Earnings Ratio vs Industry
How does VITR's PE Ratio compare vs other companies in the SE Biotechs Industry?
Price-To-Sales vs Industry: VITR is good value based on its Price-To-Sales Ratio (6.5x) compared to the Swedish Biotechs industry average (14.2x).
Price to Sales Ratio vs Fair Ratio
What is VITR's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 6.5x |
| Fair PS Ratio | 4.6x |
Price-To-Sales vs Fair Ratio: VITR is expensive based on its Price-To-Sales Ratio (6.5x) compared to the estimated Fair Price-To-Sales Ratio (4.6x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | SEK 167.10 | SEK 231.67 +38.6% | 10.3% | SEK 265.00 | SEK 210.00 | n/a | 3 |
| Jun ’25 | SEK 184.70 | SEK 231.67 +25.4% | 10.3% | SEK 265.00 | SEK 210.00 | n/a | 3 |
| May ’25 | SEK 166.30 | SEK 231.67 +39.3% | 10.3% | SEK 265.00 | SEK 210.00 | n/a | 3 |
| Apr ’25 | SEK 201.00 | SEK 248.33 +23.5% | 6.6% | SEK 270.00 | SEK 230.00 | n/a | 3 |
| Mar ’25 | SEK 184.00 | SEK 248.33 +35.0% | 6.6% | SEK 270.00 | SEK 230.00 | n/a | 3 |
| Feb ’25 | SEK 166.10 | SEK 241.67 +45.5% | 8.7% | SEK 270.00 | SEK 220.00 | n/a | 3 |
| Jan ’25 | SEK 194.70 | SEK 255.00 +31.0% | 7.3% | SEK 280.00 | SEK 235.00 | n/a | 3 |
| Dec ’24 | SEK 182.30 | SEK 250.00 +37.1% | 9.8% | SEK 280.00 | SEK 220.00 | n/a | 3 |
| Nov ’24 | SEK 144.60 | SEK 256.67 +77.5% | 12.9% | SEK 300.00 | SEK 220.00 | n/a | 3 |
| Oct ’24 | SEK 147.00 | SEK 281.67 +91.6% | 5.1% | SEK 300.00 | SEK 265.00 | n/a | 3 |
| Sep ’24 | SEK 150.40 | SEK 281.67 +87.3% | 5.1% | SEK 300.00 | SEK 265.00 | n/a | 3 |
| Aug ’24 | SEK 164.20 | SEK 281.67 +71.5% | 5.1% | SEK 300.00 | SEK 265.00 | n/a | 3 |
| Jul ’24 | SEK 209.40 | SEK 315.00 +50.4% | 4.7% | SEK 330.00 | SEK 295.00 | SEK 172.90 | 3 |
| Jun ’24 | SEK 220.20 | SEK 321.67 +46.1% | 6.0% | SEK 340.00 | SEK 295.00 | SEK 184.70 | 3 |
| May ’24 | SEK 230.40 | SEK 321.67 +39.6% | 6.0% | SEK 340.00 | SEK 295.00 | SEK 166.30 | 3 |
| Apr ’24 | SEK 215.20 | SEK 318.33 +47.9% | 7.5% | SEK 340.00 | SEK 285.00 | SEK 201.00 | 3 |
| Mar ’24 | SEK 213.00 | SEK 318.33 +49.5% | 7.5% | SEK 340.00 | SEK 285.00 | SEK 184.00 | 3 |
| Feb ’24 | SEK 229.80 | SEK 335.00 +45.8% | 1.5% | SEK 340.00 | SEK 330.00 | SEK 166.10 | 2 |
| Jan ’24 | SEK 186.20 | SEK 335.00 +79.9% | 1.5% | SEK 340.00 | SEK 330.00 | SEK 194.70 | 2 |
| Dec ’23 | SEK 197.20 | SEK 260.00 +31.8% | 40.8% | SEK 340.00 | SEK 110.00 | SEK 182.30 | 3 |
| Nov ’23 | SEK 181.20 | SEK 260.00 +43.5% | 40.8% | SEK 340.00 | SEK 110.00 | SEK 144.60 | 3 |
| Oct ’23 | SEK 159.00 | SEK 405.00 +154.7% | 1.2% | SEK 410.00 | SEK 400.00 | SEK 147.00 | 2 |
| Sep ’23 | SEK 248.60 | SEK 405.00 +62.9% | 1.2% | SEK 410.00 | SEK 400.00 | SEK 150.40 | 2 |
| Aug ’23 | SEK 329.40 | SEK 405.00 +23.0% | 1.2% | SEK 410.00 | SEK 400.00 | SEK 164.20 | 2 |
| Jul ’23 | SEK 247.00 | SEK 425.50 +72.3% | 3.6% | SEK 441.00 | SEK 410.00 | SEK 209.40 | 2 |
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.